UCB SA (UCB.BR)
EUR 187.45
(0.83%)
EUR 187.45
(0.83%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.25 Billion EUR | -4.8% |
| 2022 | 5.51 Billion EUR | -4.5% |
| 2021 | 5.77 Billion EUR | 8.04% |
| 2020 | 5.34 Billion EUR | 8.83% |
| 2019 | 4.91 Billion EUR | 6.07% |
| 2018 | 4.63 Billion EUR | 3.53% |
| 2017 | 4.47 Billion EUR | 7.89% |
| 2016 | 4.14 Billion EUR | 6.99% |
| 2015 | 3.87 Billion EUR | 15.91% |
| 2014 | 3.34 Billion EUR | 6.73% |
| 2013 | 3.13 Billion EUR | -9.5% |
| 2012 | 3.46 Billion EUR | 6.65% |
| 2011 | 3.24 Billion EUR | 0.87% |
| 2010 | 3.21 Billion EUR | 3.27% |
| 2009 | 3.11 Billion EUR | -13.47% |
| 2008 | 3.6 Billion EUR | -0.69% |
| 2007 | 3.62 Billion EUR | 43.72% |
| 2006 | 2.52 Billion EUR | 7.77% |
| 2005 | 2.34 Billion EUR | -33.76% |
| 2004 | 3.53 Billion EUR | 6.21% |
| 2003 | 3.32 Billion EUR | -40.99% |
| 2002 | 5.63 Billion EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.79 Billion EUR | 0.0% |
| 2023 Q2 | 2.58 Billion EUR | 0.0% |
| 2023 FY | 5.25 Billion EUR | -4.8% |
| 2023 Q4 | 2.66 Billion EUR | 0.0% |
| 2022 FY | 5.51 Billion EUR | -4.5% |
| 2022 Q2 | 2.92 Billion EUR | 0.0% |
| 2022 Q4 | 2.59 Billion EUR | 0.0% |
| 2021 Q2 | 2.77 Billion EUR | 0.0% |
| 2021 FY | 5.77 Billion EUR | 8.04% |
| 2021 Q4 | 2.99 Billion EUR | 0.0% |
| 2020 FY | 5.34 Billion EUR | 8.83% |
| 2020 Q4 | 2.73 Billion EUR | 0.0% |
| 2020 Q2 | 2.6 Billion EUR | 0.0% |
| 2019 Q4 | 2.59 Billion EUR | 0.0% |
| 2019 FY | 4.91 Billion EUR | 6.07% |
| 2019 Q2 | 2.32 Billion EUR | 0.0% |
| 2018 Q2 | 2.26 Billion EUR | 0.0% |
| 2018 FY | 4.63 Billion EUR | 3.53% |
| 2017 Q4 | 2.3 Billion EUR | 0.0% |
| 2017 FY | 4.47 Billion EUR | 7.89% |
| 2017 Q2 | 2.17 Billion EUR | 0.0% |
| 2016 FY | 4.14 Billion EUR | 6.99% |
| 2016 Q2 | 1.99 Billion EUR | 0.0% |
| 2015 FY | 3.87 Billion EUR | 15.91% |
| 2015 Q4 | 1.95 Billion EUR | 0.0% |
| 2015 Q2 | 1.91 Billion EUR | 0.0% |
| 2014 Q4 | 1.75 Billion EUR | 0.0% |
| 2014 FY | 3.34 Billion EUR | 6.73% |
| 2014 Q2 | 1.59 Billion EUR | 0.0% |
| 2013 Q4 | 1.47 Billion EUR | 0.0% |
| 2013 Q2 | 1.65 Billion EUR | 0.0% |
| 2013 FY | 3.13 Billion EUR | -9.5% |
| 2012 Q3 | 865.5 Million EUR | 0.0% |
| 2012 FY | 3.46 Billion EUR | 6.65% |
| 2012 Q4 | 852.75 Million EUR | -1.47% |
| 2012 Q2 | 865.5 Million EUR | 0.0% |
| 2012 Q1 | 865.5 Million EUR | 0.0% |
| 2011 Q1 | 811.5 Million EUR | 0.0% |
| 2011 Q2 | 811.5 Million EUR | 0.0% |
| 2011 Q3 | 811.5 Million EUR | 0.0% |
| 2011 Q4 | 865.5 Million EUR | 6.65% |
| 2011 FY | 3.24 Billion EUR | 0.87% |
| 2010 Q4 | 811.5 Million EUR | 0.87% |
| 2010 Q2 | 804.5 Million EUR | 0.0% |
| 2010 Q3 | 804.5 Million EUR | 0.0% |
| 2010 Q1 | 804.5 Million EUR | 0.0% |
| 2010 FY | 3.21 Billion EUR | 3.27% |
| 2009 Q4 | 804.5 Million EUR | 3.27% |
| 2009 FY | 3.11 Billion EUR | -13.47% |
| 2009 Q2 | 779 Million EUR | 0.0% |
| 2009 Q3 | 779 Million EUR | 0.0% |
| 2009 Q1 | 779 Million EUR | 0.0% |
| 2008 Q3 | 900.25 Million EUR | 0.0% |
| 2008 FY | 3.6 Billion EUR | -0.69% |
| 2008 Q1 | 900.25 Million EUR | 0.0% |
| 2008 Q2 | 900.25 Million EUR | 0.0% |
| 2008 Q4 | 779 Million EUR | -13.47% |
| 2007 Q4 | 900.25 Million EUR | -0.69% |
| 2007 FY | 3.62 Billion EUR | 43.72% |
| 2007 Q3 | 906.5 Million EUR | 0.0% |
| 2007 Q2 | 906.5 Million EUR | 0.0% |
| 2007 Q1 | 906.5 Million EUR | 0.0% |
| 2006 Q3 | 630.75 Million EUR | 0.0% |
| 2006 Q4 | 906.5 Million EUR | 43.72% |
| 2006 Q2 | 630.75 Million EUR | 0.0% |
| 2006 FY | 2.52 Billion EUR | 7.77% |
| 2006 Q1 | 630.75 Million EUR | 0.0% |
| 2005 Q4 | 630.75 Million EUR | 7.77% |
| 2005 FY | 2.34 Billion EUR | -33.76% |
| 2005 Q2 | 585.25 Million EUR | 0.0% |
| 2005 Q3 | 585.25 Million EUR | 0.0% |
| 2005 Q1 | 585.25 Million EUR | 0.0% |
| 2004 Q2 | 883.54 Million EUR | 0.0% |
| 2004 FY | 3.53 Billion EUR | 6.21% |
| 2004 Q1 | 883.54 Million EUR | 0.0% |
| 2004 Q3 | 883.54 Million EUR | 0.0% |
| 2004 Q4 | 585.25 Million EUR | -33.76% |
| 2003 Q4 | 883.54 Million EUR | 6.21% |
| 2003 Q3 | 831.89 Million EUR | 0.0% |
| 2003 Q1 | 831.89 Million EUR | 0.0% |
| 2003 Q2 | 831.89 Million EUR | 0.0% |
| 2003 FY | 3.32 Billion EUR | -40.99% |
| 2002 Q3 | 1.4 Billion EUR | 0.0% |
| 2002 Q2 | 1.4 Billion EUR | 0.0% |
| 2002 Q1 | 1.4 Billion EUR | 0.0% |
| 2002 FY | 5.63 Billion EUR | 0.0% |
| 2002 Q4 | 831.89 Million EUR | -40.99% |
| 2001 Q4 | 1.4 Billion EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -113089.655% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -113555.053% |
| Adocia SA | 2.15 Million EUR | -244179.07% |
| Aelis Farma SA | 9.05 Million EUR | -57907.51% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -166577.245% |
| genOway Société anonyme | 20.04 Million EUR | -26099.241% |
| IntegraGen SA | 12.53 Million EUR | -41790.553% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -1750368.28% |
| Neovacs S.A. | 533.41 Thousand EUR | -984504.771% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -312237.386% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -26530512.245% |
| Sensorion SA | 4.74 Million EUR | -110630.11% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1772242.414% |
| TME Pharma N.V. | 17 Thousand EUR | -30894017.647% |
| Valbiotis SA | 4.73 Million EUR | -110865.561% |
| TheraVet SA | 1.07 Million EUR | -487073.66% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -291677.778% |
| argenx SE | 1.13 Billion EUR | -363.014% |
| BioSenic S.A. | 543 Thousand EUR | -967119.153% |
| Celyad Oncology SA | 102 Thousand EUR | -5148919.608% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | -2090.853% |
| Genfit S.A. | 28.56 Million EUR | -18286.137% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -251553.091% |
| Innate Pharma S.A. | 51.9 Million EUR | -10019.266% |
| Inventiva S.A. | 17.47 Million EUR | -29950.924% |
| MaaT Pharma SA | 2.22 Million EUR | -235627.11% |
| MedinCell S.A. | 9.16 Million EUR | -57236.245% |
| Nanobiotix S.A. | 30.05 Million EUR | -17372.886% |
| Onward Medical N.V. | 532 Thousand EUR | -987118.045% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -36907.776% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -235732.959% |
| Oxurion NV | 263 Thousand EUR | -1996858.175% |
| Pharming Group N.V. | 245.31 Million EUR | -2040.912% |
| Poxel S.A. | 1.98 Million EUR | -265018.627% |
| GenSight Biologics S.A. | 1.26 Million EUR | -414422.494% |
| Transgene SA | 1.18 Million EUR | -443481.081% |
| Financière de Tubize SA | - EUR | -Infinity% |
| Valneva SE | 153.71 Million EUR | -3316.779% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 145182.873% |